QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)

Amgen (AMGN) Stock Forecast, Price & News

-2.05 (-0.76%)
(As of 09/21/2023 ET)
Today's Range
50-Day Range
52-Week Range
2.44 million shs
Average Volume
2.46 million shs
Market Capitalization
$144.11 billion
P/E Ratio
Dividend Yield
Price Target

Amgen MarketRank™ Forecast

Analyst Rating
2.40 Rating Score
1.5% Downside
$265.44 Price Target
Short Interest
1.16% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
1.00mentions of Amgen in the last 14 days
Based on 23 Articles This Week
Insider Trading
Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth
From $18.35 to $19.92 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.14 out of 5 stars

Medical Sector

18th out of 961 stocks

Biological Products, Except Diagnostic Industry

3rd out of 159 stocks

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Price History

AMGN Stock News Headlines

Flee to Healthcare Stocks if Recession Rears its Head? (AMGN)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
3 Growth Stocks to Buy in September (AMGN)
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (AMGN)
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Is Amazon a Blue Chip Stock? (AMGN)
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat.
20 Best Healthcare Dividend Stocks to Invest in (AMGN)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
Why Shares of Neumora Therapeutics Slumped This Week
Get Your Cash Out of U.S. Banks Immediately
Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
Argus Increases Amgen (NASDAQ:AMGN) Price Target to $280.00
Amgen (NASDAQ:AMGN) Sees Large Volume Increase
Amgen Unusual Options Activity
Amgen-partnered AI biotech startup brings in $273M
Should You Consider Selling Amgen (AMGN)?
Q4 2023 EPS Estimates for Amgen Inc. Boosted by Analyst (NASDAQ:AMGN)
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Last Earnings
Ex-Dividend for 9/8 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$6.55 billion
Pretax Margin


Sales & Book Value

Annual Sales
$26.32 billion
Cash Flow
$24.81 per share
Book Value
$6.86 per share


Free Float
Market Cap
$144.14 billion

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Robert A. BradwayMr. Robert A. Bradway (Age 60)
    Chairman, CEO & Pres
    Comp: $5.49M
  • Mr. Peter H. GriffithMr. Peter H. Griffith (Age 64)
    Exec. VP & CFO
    Comp: $2.57M
  • Mr. Esteban Santos (Age 55)
    Exec. VP of Operations
    Comp: $2.52M
  • Dr. David M. Reese M.D. (Age 60)
    Exec. VP of R&D
    Comp: $2.83M
  • Mr. Murdo GordonMr. Murdo Gordon (Age 56)
    Exec. VP of Global Commercial Operations
    Comp: $2.72M
  • Mr. Matthew C. Busch (Age 49)
    Chief Accounting Officer & VP of Fin.
  • Mr. Mike Zahigian
    Sr. VP & Chief Information Officer
  • Mr. Arvind Sood
    VP of Investor Relations
  • Mr. Jonathan P. GrahamMr. Jonathan P. Graham (Age 62)
    Exec. VP, Gen. Counsel & Sec.
  • Ms. Nancy A. GrygielMs. Nancy A. Grygiel (Age 55)
    Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price forecast for 2023?

15 Wall Street analysts have issued 12-month price targets for Amgen's shares. Their AMGN share price forecasts range from $200.00 to $320.00. On average, they anticipate the company's share price to reach $265.44 in the next twelve months. This suggests that the stock has a possible downside of 1.5%.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2023?

Amgen's stock was trading at $262.64 at the beginning of 2023. Since then, AMGN stock has increased by 2.6% and is now trading at $269.41.
View the best growth stocks for 2023 here

Are investors shorting Amgen?

Amgen saw a decline in short interest in August. As of August 31st, there was short interest totaling 6,200,000 shares, a decline of 11.8% from the August 15th total of 7,030,000 shares. Based on an average daily volume of 2,520,000 shares, the short-interest ratio is currently 2.5 days. Approximately 1.2% of the company's stock are short sold.
View Amgen's Short Interest

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AMGN earnings forecast

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Thursday, August, 3rd. The medical research company reported $5.00 EPS for the quarter, topping the consensus estimate of $4.44 by $0.56. The medical research company had revenue of $7 billion for the quarter, compared to analysts' expectations of $6.66 billion. Amgen had a net margin of 30.02% and a trailing twelve-month return on equity of 196.60%. The firm's revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $4.65 EPS.
Read the conference call transcript

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, August 1st. Stockholders of record on Friday, August 18th will be paid a dividend of $2.13 per share on Friday, September 8th. This represents a $8.52 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for AMGN

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.22%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 57.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.77% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $17.80-$18.80 for the period, compared to the consensus earnings per share estimate of $17.73. The company issued revenue guidance of $26.6-$27.4 billion, compared to the consensus revenue estimate of $27.02 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (57.86%), BlackRock Inc. (8.78%), State Street Corp (5.44%), Geode Capital Management LLC (2.21%), Charles Schwab Investment Management Inc. (2.10%) and Capital Research Global Investors (1.79%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $269.41.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $144.11 billion and generates $26.32 billion in revenue each year. The medical research company earns $6.55 billion in net income (profit) each year or $14.83 on an earnings per share basis.

How many employees does Amgen have?

The company employs 25,200 workers across the globe.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -